|
|
Post by nimrod71 on Oct 26, 2016 7:46:35 GMT -5
Kaleo, which makes the Auvi-Q, will reintroduce the epinephrine auto-injector at a "very, very low" cost to patients, said Kaleo CEO Spencer Williamson. Allegedly will be out first half of 2017.
|
|
|
|
Post by lakers on Oct 26, 2016 12:21:22 GMT -5
|
|
|
|
Post by lennymnkd on Oct 26, 2016 14:19:18 GMT -5
What does this mean for us / will we be the better mousetrap ?
|
|
|
|
Post by peppy on Oct 26, 2016 14:25:05 GMT -5
What does this mean for us / will we be the better mousetrap ? I think it means this. (Nothing)
Announcements, announcements, announcements!
What a terrible way to die,
A terrible way to die,
A terrible way to be talked to death.
A terrible way to die.
|
|
|
|
Post by nimrod71 on Oct 26, 2016 15:58:26 GMT -5
What does this mean for us / will we be the better mousetrap ? It means another option is going to beat us to market, zero chance Matt gets another product approved by mid 2017. Also if this Auvi-Q thingy is going to be as cheap as they are saying doesn't sound like much of a chance for another third option to be profitable. |
|
|
|
Post by op2778 on Oct 26, 2016 16:10:26 GMT -5
I can assure you that we will love to be a 3rd option, but the truth is that we will never get The product to The market.
epi inhale is just another Matt EPIC fary tale.
op
|
|
|
|
Post by MnkdWASmyRtrmntPlan on Oct 26, 2016 16:20:28 GMT -5
I believe you are all correct about epihale. But, I never pinned much on that anyway. That was just the next possible idea. Immediate survival is our only concern now.
|
|
|
|
Post by nadathing on Oct 26, 2016 20:29:06 GMT -5
They announced that epi would be going to trial in 2017, but we can't even find a partner. My guess is it is going nowhere.
|
|
